Search
Dantrolene
go.drugbank.com/drugs/DB01219ApprovedInvestigationalChemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin.
Emtricitabine
go.drugbank.com/drugs/DB00879ApprovedInvestigationalEmtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults or combined with tenofovir alafenamide for the prevention of HIV-1 infection in high risk adolescents and adults....
Omaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigationalTherefore, the use of Nrf2 activators such as omaveloxolone represents a therapeutic advantage in this group of patients. … [A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress.
Parethoxycaine
go.drugbank.com/drugs/DB19380ApprovedWithdrawnParethoxycaine is a local anesthetic that was previously approved in the US.
Rauwolfia serpentina root
go.drugbank.com/drugs/DB09363InvestigationalReserpine is derived from Rauwolfia serpentina, and was commonly used as an antihypertensive agent in the 1950s [L1621]. Rauwolfia serpentina is also commonly referred to as _Sarpaghanda_ [A32097].
Fomivirsen
go.drugbank.com/drugs/DB06759ApprovedWithdrawnAs a complementary nucleotide to the messenger RNA of the major immediate-early region proteins of human cytomegalovirus, it disrupts the replication of the virus through an antisense mechanism [L1428]
Camostat
go.drugbank.com/drugs/DB13729Investigational[A193842,A193848] It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice.
Pipecuronium
go.drugbank.com/drugs/DB01338ApprovedInvestigationalWithdrawnPipecuronium is a piperazinyl androstane derivative which is a non-depolarizing neuromuscular blocking agent.
Temsirolimus
go.drugbank.com/drugs/DB06287ApprovedInvestigationalTemsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.